Heparan sulfate mediates amyloid-beta internalization and cytotoxicity

Glycobiology

Volumn 20, Issue 5, 2010, Pages 533-541

  Sandwall, Elina ^a   O'Callaghan, Paul ^b   Zhang, Xiao ^b   Lindahl, Ulf ^a   Lannfelt, Lars ^b   Li, Jin Ping ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

A ; Cytotoxicity; Heparan sulfate; Heparanase; Heparin

Indexed keywords

AMYLOID BETA PROTEIN; HEPARAN SULFATE; HEPARANASE; HEPARIN;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; BRAIN BLOOD VESSEL; CELL PROTECTION; CELL SURFACE; CELL VIABILITY; CHO CELL; CONTROLLED STUDY; CYTOTOXICITY; EMBRYO; ENDOTHELIUM CELL; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; INTERNALIZATION; NERVOUS TISSUE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN INTERACTION; UMBILICAL VEIN; VASCULAR ENDOTHELIUM; WILD TYPE;

AMYLOID BETA-PROTEIN; ANIMALS; CELL SURVIVAL; CELLS, CULTURED; CHO CELLS; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; GLUCURONIDASE; HEPARIN; HEPARITIN SULFATE; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP;

CRICETULUS GRISEUS;

EID: 77952872366     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwp205     Document Type: Article

References (44)

1. Bergamaschini L, Donarini C, Rossi E, Luigi A, Vergani C, De Simoni MG. 2002. Heparin attenuates cytotoxic and inammatory activity of Alzheimer amyloid-beta in vitro. Neurobiol Aging. 23:531-536.
2. Bergamaschini L, Rossi E, Storini C, Pizzimenti S, Distaso M, Perego C, De Luigi A, Vergani C, De Simoni MG. 2004. Peripheral treatment with enoxaparin, a low molecular weight heparin, reduces plaques and beta-amyloid accumulation in a mouse model of Alzheimer's disease. J Neurosci. 24:4181-4186.
3. Bishop JR, Schuksz M, Esko JD. 2007. Heparan sulphate proteoglycans netune mammalian physiology. Nature. 446:1030-1037.
4. Chafekar SM, Baas F, Scheper W. 2008. Oligomer-specific Abeta toxicity in cell models is mediated by selective uptake. Biochim Biophys Acta. 1782:523-531.
5. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH. 2005. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci. 8:79-84.
6. Demuro A, Mina E, Kayed R, Milton SC, Parker I, Glabe CG. 2005. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem. 280:17294-17300.
7. Donnini S, Cantara S, Morbidelli L, Giachetti A, Ziche M. 2006. FGF-2 overexpression opposes the beta amyloid toxic injuries to the vascular endothelium. Cell Death Differ. 13:1088-1096.
8. Escobar Galvis ML, Jia J, Zhang X, Jastrebova N, Spillmann D, Gottfridson E, van Kuppevelt TH, Zcharia E, Vlodavsky I, Lindahl U, et al. 2007. Transgenic or tumor-induced expression of heparanase upregulates sulfation of heparan sulfate. Nat Chem Biol. 3:773-778.
9. Geylis V, Steinitz M. 2006. Immunotherapy of Alzheimer's disease (AD): From murine models to anti-amyloid beta (Abeta) human monoclonal antibodies. Autoimmun Rev. 5:33-39.
10. Giulian D, Haverkamp LJ, Yu J, Karshin W, Tom D, Li J, Kazanskaia A, Kirkpatrick J, Roher AE. 1998. The HHQK domain of beta-amyloid provides a structural basis for the immunopathology of Alzheimer's disease. J Biol Chem. 273:29719-29726.
11. Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA, Klein WL. 2003. Alzheimer's disease-affected brain: Presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA. 100:10417-10422.
12. Gouras GK, Tsai J, Naslund J, Vincent B, Edgar M, Checler F, Greenfield JP, Haroutunian V, Buxbaum JD, Xu H, et al. 2000. Intraneuronal Abeta42 accumulation in human brain. Am J Pathol. 156:15-20.
13. Hijazi N, Kariv-Inbal Z, Gasset M, Gabizon R. 2005. PrPSc incorporation to cells requires endogenous glycosaminoglycan expression. J Biol Chem. 280:17057-17061.
14. Jan A, Gokce O, Luthi-Carter R, Lashuel HA. 2008. The ratio of monomeric to aggregated forms of Abeta40 and Abeta42 is an important determinant of amyloid-beta aggregation, fibrillogenesis, and toxicity. J Biol Chem. 283:28176-28189.
15. Ledin J, Staatz W, Li JP, Gotte M, Selleck S, Kjellen L, Spillmann D. 2004. Heparan sulfate structure in mice with genetically modified heparan sulfate production. J Biol Chem. 279:42732-42741.
16. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH. 2006. A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 440:352-357.
17. Li JP, Galvis ML, Gong F, Zhang X, Zcharia E, Metzger S, Vlodavsky I, Kisilevsky R, Lindahl U. 2005. In vivo fragmentation of heparan sulfate by heparanase overexpression renders mice resistant to amyloid protein A amyloidosis. Proc Natl Acad Sci USA. 102:6473-6477.
18. Lidholt K, Weinke JL, Kiser CS, Lugemwa FN, Bame KJ, Cheifetz S, Massague J, Lindahl U, Esko JD. 1992. A single mutation affects both Nacetylglucosaminyltransferase and glucuronosyltransferase activities in a Chinese hamster ovary cell mutant defective in heparan sulfate biosynthesis. Proc Natl Acad Sci USA. 89:2267-2271.
19. Lindahl B, Westling C, Gimenez-Gallego G, Lindahl U, Salmivirta M. 1999. Common binding sites for beta-amyloid fibrils and fibroblast growth factor2 in heparan sulfate from human cerebral cortex. J Biol Chem. 274:30631-30635.
20. Lindahl U, Li JP. 2009. Interactions between heparan sulfate and proteins-design and functional implications. Int Rev Cell Mol Biol. 276:105-159.
21. Loo DT, Copani A, Pike CJ, Whittemore ER, Walencewicz AJ, Cotman CW. 1993. Apoptosis is induced by beta-amyloid in cultured central nervous system neurons. Proc Natl Acad Sci USA. 90:7951-7955.
22. Lorenzo A, Yankner BA. 1994. Beta-amyloid neurotoxicity requires bril formation and is inhibited by congo red. Proc Natl Acad Sci USA. 91: 12243-12247.
23. Maccarana M, Sakura Y, Tawada A, Yoshida K, Lindahl U. 1996. Domain structure of heparan sulfates from bovine organs. J Biol Chem. 271:17804-17810.
24. Mok SS, Losic D, Barrow CJ, Turner BJ, Masters CL, Martin LL, Small DH. 2006. The beta-amyloid peptide of Alzheimer's disease decreases adhesion of vascular smooth muscle cells to the basement membrane. J Neurochem. 96:53-64.
25. Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods. 65: 55-63.
26. Narindrasorasak S, Lowery D, Gonzalez-DeWhitt P, Poorman RA, Greenberg B, Kisilevsky R. 1991. High affnity interactions between the Alzheimer's beta-amyloid precursor proteins and the basement membrane form of heparan sulfate proteoglycan. J Biol Chem. 266:12878-12883.
27. Nasser NJ, Nevo E, Shafat I, Ilan N, Vlodavsky I, Avivi A. 2005. Adaptive evolution of heparanase in hypoxia-tolerant Spalax: Gene cloning and identification of a unique splice variant. Proc Natl Acad Sci USA. 102:15161-15166.
28. O'Callaghan P, Sandwall E, Li JP, Yu H, Ravid R, Guan ZZ, van Kuppevelt TH, Nilsson LN, Ingelsson M, Hyman BT, et al. 2008. Heparan sulfate accumulation with Abeta deposits in Alzheimer's disease and Tg2576 mice is contributed by glial cells. Brain Pathol. 18:548-561.
29. Parish CR. 2006. The role of heparan sulphate in inflammation. Nat Rev Immunol. 6:633-643.
30. Pollack SJ, Sadler II, Hawtin SR, Tailor VJ, Shearman MS. 1995. Sulfated glycosaminoglycans and dyes attenuate the neurotoxic effects of beta-amyloid in rat PC12 cells. Neurosci Lett. 184:113-116.
31. Sandwall E, Bodevin S, Nasser NJ, Nevo E, Avivi A, Vlodavsky I, Li JP. 2009. Molecular structure of heparan sulfate from spalax: Implications of heparanase and hypoxia. J Biol Chem. 284:3814-3822.
32. Selkoe DJ. 2001. Alzheimer's disease: Genes, proteins, and therapy. Physiol Rev. 81:741-766.
33. Selkoe DJ. 2008. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res. 192:106-113.
34. Shively JE, Conrad HE. 1976. Nearest neighbor analysis of heparin: identification and quantitation of the products formed by selective depolymerization procedures. Biochemistry. 15:3943-3950.
35. Snow AD, Mar H, Nochlin D, Kimata K, Kato M, Suzuki S, Hassell J, Wight TN. 1988. The presence of heparan sulfate proteoglycans in the neuritic plaques and congophilic angiopathy in Alzheimer's disease. Am J Pathol. 133:456-463.
36. Snow AD, Sekiguchi RT, Nochlin D, Kalaria RN, Kimata K. 1994. Heparan sulfate proteoglycan in diffuse plaques of hippocampus but not of cerebellum in Alzheimer's disease brain. Am J Pathol. 144:337-347.
37. Stanford KI, Bishop JR, Foley EM, Gonzales JC, Niesman IR, Witztum JL, Esko JD. 2009. Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice. J Clin Invest. 119:3236-3245.
38. Thal DR, Griffin WS, de Vos RA, Ghebremedhin E. 2008. Cerebral amyloid angiopathy and its relationship to Alzheimer's disease. Acta Neuropathol. 115:599-609.
39. van Horssen J, Otte-Holler I, David G, Maat-Schieman ML, van den Heuvel LP, Wesseling P, de Waal RM, Verbeek MM. 2001. Heparan sulfate proteoglycan expression in cerebrovascular amyloid beta deposits in Alzheimer's disease and hereditary cerebral hemorrhage with amyloidosis (Dutch) brains. Acta Neuropathol (Berl). 102:604-614.
40. van Horssen J, Wesseling P, van den Heuvel LP, de Waal RM, Verbeek MM. 2003. Heparan sulphate proteoglycans in Alzheimer's disease and amyloidrelated disorders. Lancet Neurol. 2:482-492.
41. Walsh DM, Selkoe DJ. 2007. A beta oligomers - A decade of discovery. J Neurochem. 101:1172-1184.
42. Williams KJ, Fuki IV. 1997. Cell-surface heparan sulfate proteoglycans: Dynamic molecules mediating ligand catabolism. Curr Opin Lipidol. 8: 253-262.
43. Wirths O, Multhaup G, Bayer TA. 2004. A modified beta-amyloid hypothesis: Intraneuronal accumulation of the beta-amyloid peptide-The first step of a fatal cascade. J Neurochem. 91:513-520.
44. Woods AG, Cribbs DH, Whittemore ER, Cotman CW. 1995. Heparan sulfate and chondroitin sulfate glycosaminoglycan attenuate beta-amyloid(25-35) induced neurodegeneration in cultured hippocampal neurons. Brain Res. 697:53-62.